Login to Your Account

No 'CRL Up and Die' on FDA's Delay of Allergan Migraine Drug

By Randy Osborne
Staff Writer

Tuesday, April 16, 2013
Disappointing, but hardly a message of doom: Such was the general view – and the opinion of the company – on Allergan Inc.'s complete response letter (CRL) for Levadex, an orally inhaled formulation of the intravenous migraine drug dihydroergotamine (DHE).

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription